My Original Investigation of Infectious Disease in the InflammoThrombotic Immunologic Response (ITIR) Disease (ITIRD) Process Began in the late 1980s - And Then Came COVID.

As mentioned previously, by 2019 I had overcome almost every possible obstacle known to man in my efforts to bring FMTVDM forward; changing the way Medical Science would both diagnose and treat health problems, including our ever increasing chronic ITIR diseases (ITIRDs).

​

I had battled back against the courts and Big Pharma [https://www.flemingmethod.com/about], I had obtained my law degree (J.D.) and learned enough to submit and obtain my patent [https://www.flemingmethod.com/copy-of-fleming-method], I had worked with others to validate my work, and I had been meeting with University officials and nuclear camera companies in an effort to launch FMTVDM.

​

By 2019 I was getting ready to sign licensing agreements and move forward and then came COVID; another ITIRD.

​

COVID-19 (Corona Virus Disease first described in 2019) had two primary effects on FMTVDM and the ITIRD theory.

 

First, like all of you, it changed what I was doing. As I mentioned previously, even though I had avoided infectious disease like the bubonic plague, I nonetheless knew that when I published the ITIRD theory in 1994 and introduced the role of infectious diseases into the theory as one of the precipitating causes leading to heart attacks, strokes, cancer, diabetes, hypertension (high blood pressure) and multiple other chronic ITIRDs, I knew that I would eventually be drawn into the infectious disease field, sooner or later. That later as it turned out would be 2019.

​

Secondly, I had a patent (FMTVDM). A patent, which measures regional blood flow and metabolic differences. Infections are associated with infected tissue undergoing increased metabolic and blood flow changes. Those changes are due to both increased metabolism from both the infected cell and the infection itself in addition to increased metabolism and blood flow as the cells involved in our immune defense system gear up and become active at the site of infection.

​

While these increases in regional blood flow and metabolism are less than seen with cancer, they are clearly more than seen in normal tissue, and so, FMTVDM can determine not only the severity of the infection but the response to treatment as well.

​

COVID, it turns out, would not only further confirm my work on Bacterially Aggravated Atherosclerosis (BAA) discussed on prior pages, but it would confirm that viruses ALSO result in ITIRDs which can be measured and treated using FMTVDM.

​

The following published research papers show just some of the work established during the COVID pandemic, the role of the ITIRD process that occurred and the role that FMTVDM played in diagnosing and finding treatments that worked for those infected.